Notice Pursuant to the National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc.

Primary source

Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.

Published

January 13, 2022

Issuing agencies

Justice DepartmentAntitrust Division

Full Text

<html>
<head>
<title>Federal Register, Volume 87 Issue 9 (Thursday, January 13, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 9 (Thursday, January 13, 2022)]
[Notices]
[Page 2182]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-00591]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Antitrust Division


Notice Pursuant to the National Cooperative Research and 
Production Act of 1993--Subcutaneous Drug Development & Delivery 
Consortium, Inc.

    Notice is hereby given that, on December 8, 2021, pursuant to 
Section 6(a) of the National Cooperative Research and Production Act of 
1993, 15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug 
Development & Delivery Consortium, Inc., (``Subcutaneous Drug 
Development & Delivery Consortium, Inc.'') has filed written 
notifications simultaneously with the Attorney General and the Federal 
Trade Commission disclosing changes in its membership. The 
notifications were filed for the purpose of extending the Act's 
provisions limiting the recovery of antitrust plaintiffs to actual 
damages under specified circumstances. Specifically, GlaxoSmithKline 
LLC, Collegeville, PA; Merck Sharp & Dohme Corp, Kenilworth, NJ; and 
Pfizer Inc., New York, NY, have been added as parties to this venture.
    No other changes have been made in either the membership or planned 
activity of the group research project. Membership in this group 
research project remains open, and Subcutaneous Drug Development & 
Delivery Consortium, Inc. intends to file additional written 
notifications disclosing all changes in membership.
    On October 26, 2020, Subcutaneous Drug Development & Delivery 
Consortium, Inc. filed its original notification pursuant to Section 
6(a) of the Act. The Department of Justice published a notice in the 
Federal Register pursuant to Section 6(b) of the Act on December 3, 
2020 (85 FR 78148).
    The last notification was filed with the Department on March 31, 
2021. A notice was published in the Federal Register pursuant to 
Section 6(b) of the Act on April 15, 2021 (86 FR 19902).

Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2022-00591 Filed 1-12-22; 8:45 am]
BILLING CODE 4410-11-P


</pre></body>
</html>

View on FederalRegister.gov →Plain-text source

Indexed from Federal Register on January 13, 2022.

This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.